Logo

Garden City
Plainview
Listen to The Optimal Health Program on WOR radio (710 on the AM dial) on Saturday mornings from 7-8 AM and WABC Radio 770 A.M. Sunday evenings from 10-11PM
Click Here for Telemedicine Consultation & Appointment
A randomized study of autologous bone marrow–derived stem cells in pediatric cardiomyopathy

Background

Bone marrow mononuclear cell fraction has been used as for dilated cardiomyopathy in adults. Although case series are reported, there are no randomized controlled studies in children.

Methods

We designed a randomized, crossover, controlled pilot study to determine safety and feasibility of intracoronary stem cell in children. The primary safety end-point was freedom from death and transplantation or any complication that could be considered related to bone marrow injection or anesthesia (e.g., infection, malignancy, anaphylaxis, renal deterioration). Other end-points were magnetic resonance imaging measurements and N-terminal prohormone brain natriuretic peptide. Participants included 10 children (mean age 7.2 years; range, 2.2–14.1 years; 6 boys) with cardiomyopathy (New York Heart Association/Ross Classification II–IV). Patients were crossed over at 6 months.

Results

The original protocol was completed by 9 patients. The safety end-point was achieved in all. Ratio of the geometric means for results effect adjusting for baseline was assessed for end-diastolic and end-systolic volumes (EDV, ESV): 0.93 for EDV (95% confidence interval 0.88–0.99, p = 0.01), indicating EDV was on average 7% lower in patients after stem cell results, and 0.90 for ESV (95% confidence interval 0.82–1.00, p = 0.05), indicating ESV was on average 10% lower after stem cell results compared with placebo. The primary efficacy end-point ejection fraction was not met.

Conclusions

Bone marrow mononuclear cell for cardiomyopathy is feasible and safe in children. Left ventricular volumes were significantly reduced 6 months after stem cell injection compared with placebo, which may reflect reverse remodeling.